← 返回

肿瘤来源的非编码 RNA 赋予肿瘤微环境免疫抑制特性

英文原题:Cancer-derived non-coding RNAs endow tumor microenvironment with immunosuppressive properties.

查看英文原题

Cancer-derived non-coding RNAs endow tumor microenvironment with immunosuppressive properties.

PubMed 2023/10/10(内容时间) Wiley Interdiscip Rev RNA Q2 · IF 4.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

非编码RNA(ncRNAs)因其在肿瘤发生和发展中的重要作用而受到广泛关注,尤其是在免疫治疗耐药方面。肿瘤免疫治疗耐药是阻碍肿瘤治疗效果的关键因素,这在很大程度上可归因于肿瘤微环境的免疫抑制特性。目前的研究表明,肿瘤来源的ncRNAs通过多种途径参与肿瘤免疫抑制微环境(TIME)的形成。它们不仅促进癌细胞表面免疫检查点配体(如PD-L1、CD47、Gal-9和CD276)的表达,还增强免疫抑制性细胞因子(如TGF-β、IL-6、IL-10、VEGF和趋化因子)的分泌。肿瘤来源的ncRNAs还可以通过细胞外囊泡转移到周围的免疫相关细胞中,从而抑制CD8+ T细胞和NK细胞的细胞毒性,抑制DC介导的抗原呈递,诱导TAMs和CAFs的免疫抑制表型转化,并增强Tregs和MDSCs的免疫抑制功能。

在此,我们总结了肿瘤来源的ncRNAs在调控TIME形成中的作用,并进一步探讨其作为预后生物标志物和免疫治疗靶点的潜在应用,这将有助于我们在未来解决TIME介导的免疫治疗耐药问题。本文归类于:疾病与发展中的RNA > 疾病中的RNA 调控RNA/RNAi/核糖开关 > 调控RNA。

展开英文摘要原文

Non-coding RNAs (ncRNAs) have attracted extensive attention due to their vital roles in tumorigenesis and progression, especially in the immunotherapy resistance. Tumor immunotherapy resistance is a crucial factor hindering the efficacy of tumor treatments, which can be largely attributed to the immunosuppressive properties of tumor microenvironment. Current studies have revealed that cancer-derived ncRNAs are involved in the formation of tumor immunosuppressive microenvironment (TIME) through multiple ways. They not only promote the expression of immune checkpoint ligands (e.

g. , PD-L1, CD47, Gal-9, and CD276) on cancer cell surfaces, but also enhance the secretion of immunosuppressive cytokines (e. g. , TGF-β, IL-6, IL-10, VEGF, and chemokines). Cancer-derived ncRNAs could also be transferred into surrounding immune-related cells through extracellular vesicles, thereby inhibiting the cytotoxicity of CD8 + T cells and NK cells, restraining the DC-mediated antigen presentation, inducing the immunosuppressive phenotype transformation of TAMs and CAFs, and enhancing the immunosuppressive functions of Tregs and MDSCs.

Herein, we summarize the roles of cancer-derived ncRNAs in regulating TIME formation and further explore their potential applications as prognostic biomarkers and immunotherapeutic targets, which will help us to address the TIME-mediated immunotherapy resistance in the future. This article is categorized under: RNA in Disease and Development > RNA in Disease Regulatory RNAs/RNAi/Riboswitches > Regulatory RNAs.

论文信息

作者
Hu T、Shi R、Gu Y、Zhou H、Fang Y、Xu T、Xu Y、Wu X
单位
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.China
文献类型
综述
期刊
Wiley interdisciplinary reviews. RNA2023 Oct 10
原文标识
PubMed 37817381 · DOI 10.1002/wrna.1822